Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, ...

Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, pledged USD 5 million to advance access to quality healthcare services for ...